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Abstract: The persistence and costs of carbonic anhydrase inhibitors + prostaglandin analogues 
(CAIs + PGAs) vs alpha-2 adrenergic agonists + prostaglandin analogues (alpha-2 agonists + 
PGAs) were compared, based on The United Kingdom General Practitioner Research Database. 
Patients with a diagnosis of ocular hypertension, glaucoma, or treated for this, were selected. 
Selected patients were prescribed CAIs + PGAs or alpha-2 agonists + PGAs. Treatment failure 
was deﬁ  ned as a prescription change (adding, removing, or replacing glaucoma treatment, 
or initiating laser or surgery). Times to treatment failure were compared with a Cox model 
adjusted by a propensity score. Mean patient age was 69.0 years and 47.6% were males. 
Treatment failure at 1 year was experienced by 58.8% receiving CAIs + PGAs and 66.0% of 
patients receiving alpha-2 agonists + PGAs (p  0.001). The hazard ratio for failure was 0.82 
(p  0.001) in favor of CAIs + PGAs after adjusting on age, gender, comorbidities, and dura-
tion of follow-up. Adjusted annual costs of glaucoma management did not differ signiﬁ  cantly 
between treatments, £440.63 with alpha-2 agonists + PGAs and £413.37 with CAIs + PGAs. 
CAIs + PGAs therapies appear more persistent than alpha-2 agonist + PGA in everyday clini-
cal practice, at a similar cost.
Keywords: glaucoma, alpha-2 adrenergic agonists, carbonic anhydrase inhibitor, prostaglandin, 
effectiveness economics, costs
Introduction
Glaucoma in various forms occurs in about 2% of the population aged more than 
40 years (Weih et al 2001). It affects children and young adults far less frequently 
than the elderly. It is estimated that in England and Wales, alone, more than 500,000 
people suffer from glaucoma and more than 70 million people are affected worldwide 
(Broman and Quigley 2006) while uncorrected refractive errors remained the major 
cause of visual impairment (Resnikoff et al 2004). In the great majority of cases the 
condition takes a chronic, slowly developing course (primary open angle glaucoma: 
POAG). Studies have demonstrated that about half of all POAG cases remain undi-
agnosed in the Western developed countries. The risk of POAG is about four times 
greater for Afro-American people than for Caucasians.
POAG usually affects both eyes and initially produces few symptoms. Eventually, 
untreated patients may become aware of severely restricted visual ﬁ  elds, or even a loss 
of central vision in the worst eye. Although blindness from glaucoma is uncommon, 
it is wholly or partially the third reason to register on the blind register for England Clinical Ophthalmology 2008:2(2) 322
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and Wales, and is the leading cause of preventable blind-
ness in the UK (Bunce and Wormald 2006). When treated, 
the probability of glaucoma-related blindness, after treat-
ment of both eyes, was estimated at 9% at 20 years after 
diagnosis (Hattenhauer et al 1998). A signiﬁ  cant risk factor 
for glaucoma blindness is advanced loss of vision when the 
condition is ﬁ  rst detected. Appropriate examinations during 
routine eye tests are therefore essential to detect glaucoma 
early and prevent signiﬁ  cant sight loss.
The annual economic burden of glaucoma in the UK 
was estimated at £62 million in direct medical costs in 1994 
(Coyle and Drummond 1995). Total annual UK costs of 
glaucoma, including direct, indirect and social cost estimated 
for the Blind Association ‘Guide Dog’ service reached £27 
billion (Guide Dog for the Blind Association).
Observational data show that frequent medication changes 
increase the costs of glaucoma treatment (Kobelt et al 1998; 
Denis et al 2004). Although the daily cost of a drug must 
be considered when prescribing (Jönsson and Krieglstein 
1998; Fiscella et al 1999; Vold et al 2002; Rylander and Vold 
2008), the impact of efﬁ  cacy should not be overlooked as 
this can diminish the need for other medical resources, such 
as ophthalmologist visits, surgery, or laser therapy (Kooner 
and Zimmerman 1987).
Increased intraocular pressure (IOP) is the main risk 
factor whereas the other causes of glaucomatous optic neu-
ropathy remain unknown. Various strategies in current use 
decrease IOP and so lower the risk of glaucoma, thereby 
limiting its development (Kass et al 2002) and controlling 
progression (Heijl et al 2002; Leske et al 2003; The AGIS 
investigators 2004; EGPS 2005). Surgery, laser therapy 
and several classes of pharmacological agents in common 
use have been introduced in recent decades. Medications 
include beta-blockers (marketed in the late 1970s), carbonic 
anhydrase inhibitors (CIAs) in the mid-1990s, and both 
alpha-2 adrenergic agonists and prostaglandin analogues 
(PGAs) in the late 1990s. It is an accepted practice to start 
treatment with a single drug, followed by drug combinations 
(whether, or not, ﬁ  xed) after an initial failure. A second-line 
monotherapy may be also used in case of failure of the ﬁ  rst 
line monotherapy. Randomized clinical trials of brimonidine 
vs brinzolamide both associated with travoprost showed a 
better IOP control in the patients treated with travoprost and 
brinzolamide (Reis et al 2006; Feldman et al 2007).
Health authorities increasingly demand documentation 
showing drug efﬁ  cacy based on prescriptions in everyday 
practice (Hjelmgren et al 2001). Retrospective cohort studies 
comparing treatments can be effective strategies to provide 
such information. Studies using the endpoint of ‘persistence’ 
or ‘adherence’ to treatment are now being applied to glaucoma 
treatment (Deschaseaux-Voinet et al 2003; Nordstrom et al 
2005; Covert and Robin 2006; Wilensky et al 2006).
An extensive source of patient data is The United King-
dom General Practitioner Research Database (UK-GPRD) 
which collects information from a representative sample of 
general practitioners (GPs) (http://www.gprd.com/home/). 
Glaucoma data, for example, are collected comprehensively 
because GPs perform a gatekeeper role in the UK. This paper 
compares the costs and effectiveness of two medications 
(alpha-2 adrenergic agonists vs carbonic anhydrase inhibi-
tors) each used in combination with a prostaglandin analogue 
as glaucoma therapy.
Materials and methods
Data sources
This study extracted data from the UK-GPRD, which is 
the world’s largest computerized database with anonymous 
longitudinal records of approximately three million patients 
in primary medical care collected continuously by general 
practitioners since 1987. Records include demographic infor-
mation (other than race) on age, gender, medical diagnosis, 
prescriptions, clinical events, and hospital referrals.
Data management
The UK-GPRD mainly reports incidences (eg, visits, drugs, 
comorbidities), hence considerable data management must 
be performed to extrapolate the prevalence of events.
Treatments are, here, represented by product names 
and dates of prescription. The main assumption was that 
carbonic anhydrase inhibitors (CAIs) or alpha-2 agonists 
were prescribed for a maximum period of 100 days which 
approximately corresponds to three eye-drop bottles. Initial 
prescriptions rarely exceeded this quantity. Two consecutive 
prescriptions for less than 100 days each were presumed to 
represent renewed therapy. Any other ophthalmic product 
prescribed during the same period was regarded as an addi-
tional treatment.
Patient selection and inclusion
Three sets of terms were used to identify the UK-GPRD 
population of patients treated for glaucoma or intra-ocular 
hypertension, as follows: (1) Diagnosis required speciﬁ  c 
‘open-angle’ and more generic ‘glaucoma’ terms that 
excluded speciﬁ  cally ‘closed-angle’, ‘angle closure’ and 
‘glaucoma due to other causes’ (eg, trauma); (2) Sur-
gery or laser terms for glaucoma were ﬂ  agged as speciﬁ  c Clinical Ophthalmology 2008:2(2) 323
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(eg, ‘laser trabeculoplasty’ and ‘iridectomy for glaucoma’) 
or non-speciﬁ  c (eg, ‘iridectomy’ not stated as for glaucoma); 
(3) Medication terms included topical or systemic glaucoma 
products deﬁ  ned by their active constituents as listed in the 
British National Formulary.
Patients of either sex were identiﬁ  ed by at least one 
GP visit documenting a clinical referral or test related to a 
glaucoma diagnostic, surgical or laser term, as above, or a 
prescription for a speciﬁ  c glaucoma product. Patients with all 
the following characteristics were included in the analysis: 
(1) a glaucoma diagnosis (as above), (2) initial treatment 
with either a CAI + PGA or an alpha-2 agonist + PGA, and 
(3) follow-up longer than 6 months once the study therapies 
were begun. Patients with pre-existing CAI or alpha-2 agonist 
treatments were excluded.
Evaluation criteria
Treatment failure was deﬁ  ned as a prescription change 
replacing or discontinuing the initial medication, or adding a 
new medication (association). Patients given laser therapy or 
surgery for glaucoma were regarded as treatment failures.
Statistical methods
Statistical analyses used SAS V9.1 software (SAS Institute; 
North Carolina, USA). Treatment groups were compared 
at baseline on demography, general comorbidities and eye 
comorbidities. Continuous variables were compared by a 
t-test after verifying normality or by a non-parametric Wil-
coxon test, in the absence of normality. Discontinuous vari-
ables were analyzed by a Chi-square test that was replaced 
by Fisher’s exact permutation test when samples were small. 
All tests were interpreted two-sided with α = 0.05.
Survival curves by treatment group were estimated 
using the Kaplan-Meier method, without adjustment. The 
treatment failure hazard-ratio between alpha-2 agonist and 
CAI was estimated by a Cox regression, with and without 
adjustment.
Unbalanced confounding factors of treatment efﬁ  cacy 
were adjusted for, using the propensity score method (Yue 
2007). The propensity score, deﬁ  ned as the conditional prob-
ability of being treated with a speciﬁ  c treatment according 
to the observed covariates, was used to balance covariates 
in the two treatment groups and so control bias. A logistic 
regression was performed to estimate a propensity score 
(probability to be treated with either alpha-2 agonist or CAI) 
for each patient. Variables (demographics, general and eye 
co-morbidity, time since diagnosis) included in the logistic 
regression were selected from univariate statistics searching 
for treatment unbalances. Then, a stepwise algorithm was 
used to select variables with an entry and exit p-value ﬁ  xed at 
0.10. Quartiles based on the estimated propensity score were 
created and included in the Cox model to obtain an adjusted 
estimate of the treatment effect (time to failure).
Collected medical resource utilization was speciﬁ  c to 
glaucoma and therefore should not be impacted by comor-
bidities, by deﬁ  nition. The only known factors contributing 
to cost is patient follow-up duration. Two sets of estimates 
were obtained by adjusting, or not adjusting, on the duration 
of follow-up. Adjustment was made by a linear regression 
model: (1) the simple model only included treatment group 
(2) the adjusted model included treatment group and unbal-
anced confounding factors.
Economic evaluation
Direct and consequential costs of glaucoma medical care 
were analyzed from the economic perspective of the UK 
National Health Service.
The UK-GPRD yielded the following glaucoma informa-
tion: (1) laser therapy and surgery, (2) hospitalizations for 
glaucoma, (3) glaucoma medication, (4) visits to GPs and 
glaucoma specialists, and (5) prescription renewals by tele-
phone. Consumption items were collected for each patient 
from the prescription to the ﬁ  nal follow-up day and included 
treatment subsequent to medication failure.
Unit costs of medication were taken from the British 
National Formulary (2005) (www.bnf.com) and did not 
include drug discounts. Unit costs for medical procedures 
(surgery, laser therapy, hospitalization, and consultations) 
were taken from Jönsson and Krieglstein (1998) and inﬂ  ated 
to the year 2005 by applying the National Health Service 
inﬂ  ation rate (Statistics of OECD). Visits to ophthalmologists 
were costed at £107 per patient hour and follow-up visits 
were assumed to last 15 minutes (Curtis and Netten A 2005). 
General practitioner visits were costed at £129 per patient 
hour and follow-up visits were assumed to last 15 minutes 
(Curtis and Netten 2005). We estimated both the total and 
annual costs of each treatment regimen.
Results
In total, 54,513 glaucoma patients were selected from the 
UK-GPRD representing all UK regions. A subgroup of 6,176 
patients met our study criteria, comprising 4,792 treated with 
CAIs + PGAs and 1,384 with alpha-2 agonists + PGAs. The 
3:1 of ratio CAIs/alpha-2 agonists showed that CAIs + PGAs 
were prescribed more frequently for glaucoma than alpha-2 
agonists + PGAs.Clinical Ophthalmology 2008:2(2) 324
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No statistically significant differences in gender 
distribution (47.6%) or age (mean 69.0 years) were found 
at inclusion between patients treated with CAIs or alpha-2 
agonists (Table 1). However, time since diagnosis was sig-
niﬁ  cantly (p  0.001) longer for the CAI group, whereas the 
mean duration of follow-up was signiﬁ  cantly (p  0.001) 
longer for alpha-2 agonist group (1,060 days) than the CAI 
group (838 days).
General health and eye comorbidity data, comprising 
all prevalent and incident events from entry into the UK-
GPRD to the exit date of the present study, are presented 
in Table 2. Statistically signiﬁ  cant differences were noted 
between the two treatment groups. As compared to CAIs, 
patients treated with alpha-2 agonists experienced more 
ocular sensory symptoms and general comorbidities, ie, 
cardiac disorders, immune system disorders, nervous system 
disorders, psychiatric disorders, and respiratory disorders. 
Neither category of comorbidities was associated with time 
to treatment failure.
One year after starting glaucoma medication, patients 
experienced less treatment failure with CAIs than with 
alpha-2 agonists (Table 3) and this advantage was 
maintained throughout the subsequent 3 years. Accordingly, 
the hazard ratio for failure was signiﬁ  cantly less with CAIs 
(OR = 0.82: p  0.0001) before adjustment and remained 
so after adjustment for age, gender, comorbidities, and 
duration of follow-up (OR = 0.82: p  0.001). Time to 
50% failure was longer with CAIs (8.5 months). Survival 
curves are shown in Figure 1.
Most of the patients were followed up until failure of 
the current treatment-line: both treatments failed for 5,734 
of 6,176 patients (92.8%) during the study period (Table 4). 
Second-line treatment for more than half of all patients was 
a switch to prostaglandin analogues (in monotherapy or in 
combination, with beta-blockers the next preference) and for 
2.9% a switch to surgery or laser therapy.
Average monthly costs associated with CAIs + PGAs 
were estimated at £33.98 per patient and were close to those 
of alpha-2 agonists + PGAs, £36.22 (Table 5). There was no 
signiﬁ  cant difference between these costs even after adjust-
ment. Average daily costs with CAIs were 98.2% of those 
with alpha-2 agonists. The adjusted annual cost difference 
of a patient receiving CAI treatment was only £27.26 less 
than for an alpha-2 agonist.
Discussion
The use of carbonic anhydrase inhibitors and prostaglan-
din analogues was compared in this study with alpha-2 
adrenergic agonists and prostaglandin analogues during 
everyday UK general practice.
Many researchers claim that non-randomized studies 
lead to unreliable results and advocate the unique use of 
randomized controlled trials (RCTs) (Dunn et al 2002). 
Despite the risk of producing biased treatment estimates, 
other authors favor the use of non-randomized studies on the 
basis that these can lead to results which may be compared 
with those reported in RCTs (Concato et al 2000). Therefore, 
sources of existing observational data can provide valuable 
information. Also, RCTs are generally conducted under 
strict protocol conditions that differ from everyday practice. 
Consequently, some authors assert that randomized studies 
do not provide information of much relevance to decision-
makers (Heckman et al 1995). Thus, while most clinical 
researchers regard observational studies as exploratory tools 
yielding results that need to be conﬁ  rmed by RCTs, non-ran-
domized studies need to be performed after RCTs to assess 
the external validity of RCT ﬁ  ndings. Our database analysis 
should be interpreted in this manner.
On the information available, we observed no socio-
demographic differences between patients receiving CAIs or 
alpha-2 agonists, except for time since diagnosis and duration 
of follow-up, despite the lack of treatment randomization. The 
latter is explained by the earlier Market Access Authorization 
of brimonidine (European Medicines Agency). General and 
ocular comorbidity differences between the treatment groups 
were not related to clinical outcomes and no adjustment was 
necessary. Nonetheless, we analyzed treatment failure both 
with and without adjustment and obtained very similar results, 
conﬁ  rming the robustness of our ﬁ  ndings. In addition, we used 
a propensity score analysis which is well accepted by health 
authorities (Yue 2004). This approach follows the recommen-
dations issued by the British Medical Journal (Mamdani et al 
2005; Normand et al 2005; Rochon et al 2005).
Table 1 Patient demography and follow-up duration
Variable Alpha-2  agonists  CAIs  p-value
 n  = 1,384 n  = 4,792
Gender    
 Male  47.8%  47.5%  0.8466
 Female  52.2%  52.5% 
Age (years)  69.2 (12.0)  68.9 (12.5)  0.6419
Time since diagnosis  4.08 [2.94]  4.51 [3.47]  0.001
(years)
Mean duration of  1,059.6 [967]  838.1 [700]  0.001
follow-up (days)
Note: (sd) [median]
Abbreviation: CAIs, carbonic anhydrase inhibitors.Clinical Ophthalmology 2008:2(2) 325
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As far as possible, taking into account the information 
available in the UK GPRD database, we gave due attention 
to controlling selection bias and confounding factors. First, 
these matters are clinically relevant as both drug classes had 
the same indications. Moreover, the choice between a CAI, 
or an alpha-2 agonist combined with a PGA, after the latter 
monotherapy has failed, is clinically important. Second, data 
were collected on available factors known to be confounded 
with treatment persistence, eg, age as a surrogate endpoint 
of glaucoma severity, eye, and general co-morbidities. Data 
on other confounding factors were not recorded in the data-
base (eg, race and IOP at treatment initiation). However, as 
the estimated propensity score may be regarded as a latent 
variable, summarizing disease severity, the reported ﬁ  ndings 
were duly adjusted. Third, baseline comparison was per-
formed and showed no major differences between the treat-
ment groups. Fourth, none of the few unbalanced variables 
was linked to treatment persistence. Hence, our propensity 
score might have led to some over-adjustment, despite 
which the adjusted results remained statistically signiﬁ  cant. 
Lastly, two adjustment procedures, ie, regression (not 
reported) and propensity scores, were used and neither 
showed any major change of treatment effect.
The larger number of patients treated with a CAI could 
have introduced a channelling bias, ie,the few severe cases 
would have been treated with the most effective drug. We 
believe that two major factors would explain this imbalance: 
(1) two CAIs were marketed (brinzolamide and dorzolamide), 
as compared to one of the alpha-2 agonists (brimonidine), and 
(2) dorzolamide market authorization and access preceded 
brimonidine by 1 year.
The number of drugs following CAI or alpha-2 agonist 
treatment failure was somewhat greater after the alpha-2 
agonists, suggesting a more frequent occurrence of severe 
cases in the latter patient group. From a strict standpoint, 
treatment group imbalance should be considered at the initia-
tion of treatments. Therefore, we did not regard subsequent 
events as factors inﬂ  uencing treatment persistence. Also, 
the initiation of a rescue treatment depends on the previ-
ous treatment and the choice should take into account the 
Table 2 Eye and general comorbidities – UK GPRD prevalence rates
Comorbity Alpha-2  agonists  CAIs  p-value
Ocular comorbidity    
Anterior eye structural changes  273 (19.7%)  1,015 (21.2%)  0.2403
Congenital eye disorders  10 (0.7%)  36 (0.8%)  0.9129
Ocular infections, irritations and inﬂ  ammations  444 (32.1%)  1,459 (30.4%)  0.2461
Ocular injuries  20 (1.4%)  66 (1.4%)  0.8496
Ocular neuro-muscular disorders  14 (1.0%)  55 (1.1%)  0.6711
Ocular sensory symptoms  12 (0.9%)  15 (0.3%)  0.0059
Retina, choroid and vitreous hemorrhages and vascular disorders  101 (7.3%)  319 (6.7%)  0.4043
Ocular hemorrhages and vascular disorders  64 (4.6%)  177 (3.7%)  0.1153
Vision disorders  262 (18.9%)  884 (18.4%)  0.6838
General comorbidity    
Blood and lymphatic disorders  162 (11.7%)  618 (12.9%)  0.2399
Cardiac disorders  698 (50.4%)  2,184 (45.6%)  0.0014
Congenital and genetic disorders  73 (5.3%)  279 (5.8%)  0.4389
Ear disorders  645 (46.6%)  2,224 (46.4%)  0.8989
Endocrine disorders  289 (20.7%)  978 (20.4%)  0.7900
Gastrointestinal  912 (65.9%)  3,182 (66.4%)  0.7256
Liver disorder  69 (5.0%)  228 (4.8%)  0.7274
Immune system disorders  700 (50.6%)  2,182 (45.5%)  0.001
Infections  1,036 (74.9%)  3,524 (73.5%)  0.3264
Injuries 630  (45.5%)  2,144  (44.7%)  0.6078
Metabolism and nutrition disorders  633 (45.7%)  2,212 (46.2%)  0.7808
Musculo-skeletal disorders  1,083 (78.3%)  3,722 (77.7%)  0.6472
Neoplasm benign and malignant  477 (34.5%)  1,709 (35.7%)  0.4116
Nervous system disorders  892 (64.5%)  2,898 (60.5%)  0.0075
Psychiatric disorders  547 (39.5%)  2,038 (42,5%)  0.0458
Renal and urinary disorders  543 (39.2%)  1,879 (39.2%)  0.9877
Respiratory disorders  1,079 (78.0%)  3,570 (74.5%)  0.0085
Skin and subcutaneous tissue disorders  932 (67.3%)  3,212 (67.0%)  0.8274
Abbreviation: CAIs, carbonic anhydrase inhibitors.Clinical Ophthalmology 2008:2(2) 326
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pharmaco-dynamics of the drugs concerned, which differ 
between CAIs and alpha-2 agonists. Lastly, the number of 
patients given surgery or laser therapy as rescue treatments, 
ie, the most severe cases, was similar.
Data management was performed ‘blind’, before any 
patient was selected, with respect to the general glaucoma 
database where all types of treatment were pooled together. 
This allowed us to minimize bias when comparing treat-
ments. Also, this approach was meaningful as the compared 
glaucoma drugs were homogenously distributed, hence 
choices made at a global level should not have impacted on 
any speciﬁ  c treatment. We performed sensitivity analyses 
on subsets of the entire glaucoma database (eg, when select-
ing the 100-day threshold) because our data management 
programs required intensive computer resources (some ﬁ  les 
exceeded 15 millions lines). Accordingly, we believe that our 
data management was fair and did not systematically bias 
treatment comparisons.
Treatment failure was signaled by a change of treatment, 
ie, adding, stopping or replacing glaucoma medication, sur-
gery or laser therapy, as is common practice with glaucoma 
analyses of claim data (Deschaseaux-Voinet et al 2003; 
Nordstrom et al 2005; Covert and Robin 2006; Wilensky 
et al 2006).
We found a signiﬁ  cantly lower rate of treatment failure 
with CAIs + PGAs over a 4 year period, according to our 
outcome deﬁ  nition. The comparison between treatment 
persistence and clinical efﬁ  cacy is not straightforward since 
the former encompasses several dimensions which are 
usually controlled in clinical trials (eg, treatment delivery, 
compliance, efﬁ  cacy, safety). Our results could be compared 
to those of Feldman et al (2007) and Reis et al (2006), who 
reported randomized, masked studies, comparing dorzol-
amide and brimonidine. Both sets of authors concluded that 
the treatments produced equivalent IOP control. Our different 
observation may be explained by several factors. First, we 
studied treatments in contrast to the two randomized trials, 
which concerned second-line treatments. Second, our study 
Table 3 Adjusted failure rates over time according to treatment
Duration of treatment  Alpha-2 agonists  CAIs
12 months  34.0%  41.2%
24 months  16.4%  22.6%
36 months  8.1%  12.7%
48 months  3.5%  6.3%
Time to 50% failure incidence   6.5  8.5
rate (month)
Abbreviation: CAIs, carbonic anhydrase inhibitors.
Figure 1 Time to failure of carbonic anhydrase inhibitors (CAIs) and alpha-2 agonists from the initiation of therapy.
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involved large patient populations recorded in the UK-GPRD 
which provided greater power to observe small signiﬁ  cant 
differences. Third, treatment acceptability may play a role. 
Although Stewart et al found both treatments to be well 
tolerated and without signiﬁ  cant effects on safety param-
eters (Stewart et al 2000), Whitson et al (2004) observed 
signiﬁ  cantly more stinging and burning with dorzolamide 
(CAI) (p  0.02) and more frequent dry eyes with brimo-
nidine (alpha-2 agonist) (p = 0.04) (Whiston et al 2004). 
Accordingly, in everyday practice it is possible that treatment 
failure may be related to unwanted effects that patients will 
not tolerate. Speciﬁ  c patient chart data should be collected 
to test this hypothesis.
The costs of CAIs + PGA were higher than the ones of 
alpha-2 + PGA while the cost of one bottle of brimonidine 
was higher (about +20%) than the average cost of the two 
CAIs participating in the analysis. This was explained by 
the longer treatment persistence of CAIs. Treatment failure 
leads to higher costs (Denis et al 2004) as conﬁ  rmed, here, 
by the nature of the rescue treatment which in most cases 
comprised the more costly prostaglandin analogues. Con-
versely, medications that would lower the failure rate should 
reduce the costs of patients who receive them. The annual 
failure rate with CAIs was signiﬁ  cantly lower over 4 years 
than for alpha-2 agonists. Hence, by delaying the need for 
more expensive glaucoma treatments, CAIs would eventu-
ally become less expensive than alpha-2 agonists. Results 
for adjusted and non-adjusted costs were presented because 
the follow-up time for patients given CAIs was longer than 
with alpha-2 agonists. Cost differences during either drug 
regimen remained non-signiﬁ  cant both with and without 
adjustment.
Our analysis has the following limitations. First, as pre-
scription renewal was not clearly documented we ﬁ  xed the 
average renewal period at 100 days, corresponding approxi-
mately to three eye-drop bottles. An eye-drop bottle contains 
ﬂ  uid for 28 days according to the summary of product char-
acteristics (Vidal 2006), with extra ﬂ  uid to replace for poor 
instillations by elderly persons (Roulland et al 2003). Thus, 
our assumption of 100 days per prescription appears reason-
able. In order to conﬁ  rm our ﬁ  ndings, experimental designs 
with prospective data collection are required to document in 
detail treatment switches and the reasons for switches. Hence, 
observational surveys recording treatment administration 
prospectively might be of scientiﬁ  c interest.
Second, reasons for modifying treatments are not 
documented in the UK-GPRD, and that limits a deﬁ  nitive 
understanding. Given this circumstance, it was assumed 
that treatment changes were made for reasons of tolerance 
or lack of efﬁ  cacy.
Table 4 Resource utilization after CAI alpha-2 agonist treatment 
failure
Rescue   Alpha-2 agonists  CAIs   Total 
treatment n  = 1,319 n  = 4,415 n  = 5,734
Number of drugs     
  No drugs  39 (3.0%)  126 (2.9%)  165 (2.9%)
  Monotherapy  854 (64.7%)  3,280 (74.3%)  4,134 (72.1%)
  2 drugs  197 (14.9%)  435 (9.9%)  632 (11.0%)
  3 drugs  223 (16.9%)  553 (12.5%)  776 (13.5%)
  4 drugs  6 (0.5%)  21 (0.5%)  27 (0.5%)
Surgery  32 (2.4%)  110 (2.5%)  142 (2.5%)
Laser therapy  7 (0.5%)  16 (0.3%)  23 (0.4%)
Drug classes     
  Beta-blocker  270 (20.5%)  1,529 (34.6%)  1,799 (31.4%)
  Prostaglandin  845 (64.1%)  2,732 (61.9%)  3,577 (62.4%)
 analogue
  Alpha-2  663 (50.3%)  345 (7.8%)  1,008 (17.6%)
  CAI  249 (18.9%)  227 (5.1%)  476 (8.3%)
Abbreviation: CAIs, carbonic anhydrase inhibitors.
Table 5 Annual average cost of glaucoma according to the treatment (£: 2005)
Cost item  Alpha-2 agonists  CAIs  p-value
Annual total costs from inclusion  413.83 (700.37)  421.11 (762.14)  0.7501
Monthly total costs from inclusion  34.01 (57.56)  34.61 (62.64)  0.7501
Drugs 23.83  (36.91)  24.44  (36.93)  ~1
  Monthly costs of drugs of study  7.29 (15.21)  9.19 (14.55)  0.0001
  Monthly costs of other drugs  16.54 (22.36)  15.25 (23.24)  0.0657
Monthly costs of consultation  8.01 (19.45)  8.30 (20.11)  0.6242
Monthly costs of hospitalization-surgery-laser therapy  2.17 (16.12)  1.88 (24.66)  ~1
Mean daily costs unadjusted  1.13 (1.92)  1.15 (2.09)  0.7501
Annual adjusted total costs  440.63  413.37  0.2327
 [401.27–480.0]  [392.32–434.41] 
Note: (sd) [CI 95%]
Abbreviation: CAIs, carbonic anhydrase inhibitors.Clinical Ophthalmology 2008:2(2) 328
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Third, the main limitation of this study was its retro-
spective design, which precluded any veriﬁ  cation of data 
accuracy. Conversely, we were able to exploit aspects of UK 
National Health Service regulations that restrict a patient’s 
access to other physicians, provide longitudinal data, and 
ensure a high standard of documentation which does not 
always apply to other health organizations. Hence, we were 
able to document previous treatments and check group com-
parability accurately, even though the internal validity of our 
survey was not equal to that of a randomized clinical trial.
Conclusion
According to the UK-GPRD information, glaucoma treat-
ment with CAIs + PGAs was more persistent in everyday 
practice than alpha-2 agonists + PGAs. Patients continued 
longer with CAIs. During 4 years of treatment the daily 
costs of a patient receiving CAIs were similar to those of 
alpha-2 agonists.
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